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Abstract
Objective: To assess whether ventilator-associated lower respiratory tract infections (VA-LRTIs) are associated with mortality
in critically ill patients with acute respiratory distress syndrome (ARDS). Materials and Methods: Post hoc analysis of pro-
spective cohort study including mechanically ventilated patients from a multicenter prospective observational study (TAVeM
study); VA-LRTI was defined as either ventilator-associated tracheobronchitis (VAT) or ventilator-associated pneumonia (VAP)
based on clinical criteria and microbiological confirmation. Association between intensive care unit (ICU) mortality in patients
having ARDS with and without VA-LRTI was assessed through logistic regression controlling for relevant confounders. Asso-
ciation between VA-LRTI and duration of mechanical ventilation and ICU stay was assessed through competing risk analysis.
Contribution of VA-LRTI to a mortality model over time was assessed through sequential random forest models. Results: The
cohort included 2960 patients of which 524 fulfilled criteria for ARDS; 21% had VA-LRTI (VAT ¼ 10.3% and VAP ¼ 10.7%). After
controlling for illness severity and baseline health status, we could not find an association between VA-LRTI and ICU mortality
(odds ratio: 1.07; 95% confidence interval: 0.62-1.83; P ¼ .796); VA-LRTI was also not associated with prolonged ICU length of
stay or duration of mechanical ventilation. The relative contribution of VA-LRTI to the random forest mortality model remained
constant during time. The attributable VA-LRTI mortality for ARDS was higher than the attributable mortality for VA-LRTI alone.
Conclusion: After controlling for relevant confounders, we could not find an association between occurrence of VA-LRTI and
ICU mortality in patients with ARDS.
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Introduction
Acute respiratory distress syndrome (ARDS) is a common and
severe condition occurring in the most severely ill patients
admitted to the intensive care unit (ICU).1 The current consen-
sus as well as older definitions all demand that oxygenation
impairment coupled with bilateral opacities on chest imaging
in the absence of signs of fluid overload must be present to
consider diagnosing ARDS.1,2
Lower respiratory tract infections (LRTIs) are a major issue
in critically ill patients, being associated with prolonged hos-
pitalization, higher costs, and possibly, an increase in mortal-
ity.3-6 In mechanically ventilated patients, ventilator-associated
LRTIs (VA-LRTIs) are stratified into ventilator-associated tra-
cheobronchitis (VAT) and ventilator-associated pneumonia
(VAP) according to the presence of new abnormal chest ima-
ging findings, which are a prerequisite for the diagnosis of
VAP.3 Since VAP may impair oxygenation, there is, therefore,
an important interplay between ARDS and VAP, which chal-
lenges both diagnoses in clinical practice. Moreover, the
impact of the occurrence of VA-LRTI in patients with ARDS
on mortality is debatable, with most reports focusing on VAP
only.4,6-8
We hypothesized that, in the context of a high mortality
scenario such as ARDS, occurrence of VA-LRTI would not
be associated with increased ICU mortality. We secondarily
hypothesized that the attributable mortality in mechanically




This is a subanalysis of a large prospective cohort of 2960
critically ill patients, which required mechanical ventilation
(MV) for more than 48 hours in 8 countries (incidence and
prognosis of ventilator-associated tracheobronchitis—
TAVeM study3). According to the Berlin definition, all
patients with ARDS were selected for this subanalysis.1
A full list of investigators is given in the Supplemental
Material.
Definitions
Only microbiologically confirmed infections were considered
for this analysis.3 A diagnosis of VA-LRTI was made when 2
of the following criteria were present: temperature > 38.5C or
< 36.5C, leukocyte count greater than 12 000 cells/mL or less
than 4000 cells/mL, and purulent secretions on tracheal aspi-
rate. Ventilator-associated lower respiratory tract infection was
stratified into VAT or VAP according to the presence or
absence of new abnormal imaging on chest radiography;
patients without new infiltrates were categorized as having
VAT, while patients with new infiltrates were considered to
have VAP.3 All chest radiographies were centrally adjudicated
by members of the steering committee.3 We only included the
first episodes of VA-LRTI occurring more than 48 hours after
starting MV. The diagnosis of ARDS was made based on the
Berlin criteria using PaO2/FiO2 (P/F) ratio
9 at the time the
patient was included in the main study; therefore, all patients
had ARDS prior to development of VA-LRTI.
End Points
The main end point was ICU mortality. Secondary end points
included ICU length of stay (LOS) and length of MV.
General Statistical Analysis
Continuous variables were compared between groups with t
test or Mann-Whitney U test according to the normality
assessment using Kolmogorov-Smirnov test. Categorical
variables were compared using w2 test or Fisher exact test,
as appropriate.
Mortality Analysis
The independent association between VA-LRTI and ICU
mortality in patients with ARDS was assessed using logistic
regression model. We defined a priori that the model would
adjust for a marker of global illness severity (Simplified Acute
Physiology Score 2 [SAPS 2]10), a marker of performance in
daily living activities (Barthel index11), worsening in gas
oxygenation, and occurrence of VA-LRTI. Two main models
were built, one grouping VAT and VAP (VA-LRTI model) and
one considering VAT and VAP individually while coded as
dummy variables. Models were bootstrapped (105 repetitions)
and bootstrap bias reported.
Attributable Mortality Analysis
For attributable mortality analysis, we elected all patients
included in the TAVeM database. A multivariate logistic
regression with ICU mortality as the dependent variable was
performed with the following predictors: SAPS 2, Barthel
index, occurrence of ARDS, and occurrence of VA-LRTI.
Interaction between occurrence of ARDS and VA-LRTI was
allowed in the model. We estimated the attributable fraction
under the hypothetical scenario where the binary exposure of
interest (ARDS or VA-LRTI) is eliminated from the population
based on a generalized linear model (ratio of counterfactual
probabilities). We calculated attributable mortality of VA-
LRTI in patients with and without ARDS. In a sensitivity
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analysis, we considered only VAP instead of VA-LRTI for
attributable mortality estimation.
Contribution of VA-LRTI to Mortality Over Time
We performed a secondary mortality analysis using sequential
random forests models to assess the impact of timing of occur-
rence of VA-LRTI on mortality in both patients with and with-
out ARDS. In this analysis, random forest models were built for
each day from the first day of follow-up until 14 days. Random
forest models are tree-based classifying methods that are useful
for classification when interactions are expected and that pro-
vide reliable estimators of variable importance.12,13 For each
day, the random forest model was performed including only
patients who were still in the ICU up to that day and who did
not have VA-LRTI up to that day. For example, the random
forest model of day 5 included only patients who were still in
the ICU at that day and who did not have VA-LRTI until then.
The model was adjusted for SAPS 2 and Barthel index. We
plotted the relative importance of the 3 variables included in
the model (SAPS 2, Barthel index, and VA-LRTI) over time.
Variable importance was defined as the mean decrease in Gini
score due to that variable in the model, which is presented as
percentage over all Gini decrease for clarity. Gini importance
measures the average gain of purity of splits in a random forest
model; the more useful a variable is, the higher the “purity” in
the nodes after splitting (ie, the more importance a variable is,
the higher will be the decrease in Gini score caused by it). This
analysis is conceptually similar to the one performed by Iwa-
shyna.14 We truncated this analysis at 14 days to the limited
number of events after the period.
Intensive Care Unit LOS and Duration of MV
The association between ICU LOS and duration of MV and
VA-LRTI was assessed using a Fine and Grey–adjusted com-
peting risk models considering death as a competitor for ICU
LOS and duration of MV. Similar to the logistic regression, the
model was adjusted by SAPS 2, Barthel index, and worsening
of oxygenation.
All analyses were performed using R project version 3.4.0
with packages tidyverse, randomForest, ggplot2, and AF.15 A P
value of .05 was considered significant for the analyses except
when mentioned.
Results
Of the initial cohort of 2960 patients, 524 fulfilled Berlin
definition for ARDS. The time course of patients in the
TAVeM database is shown in Figure 1, with sequential
100% stacked barplots representing the proportion of patients
on a given status at a given day; panels B and C show the
information for patients with and without ARDS. Patients
were categorized according to the clinical status (at the ICU
on MV, at the ICU not on MV, and discharged or dead) stra-
tified by the presence of VA-LRTI up to that day (see Figure 1
for details). Time trend of patients with and without ARDS
was similar, with some particularities such as the higher mor-
tality in patients with ARDS (both in patients with [red color]
or without [dark green color] LRTI) and the reduced propor-
tion of patients discharged alive after VA-LRTI in the ARDS
group (noticed by the reduced cyan area). These differences,
however, were small.
Figure 1. Proportion of patients at a given status from admission until 28 days (A), stratified according to the absence (B) or presence (C) of
acute respiratory distress syndrome (ARDS). There are 4 possible status (on mechanical ventilation: MV[þ]; not on MV but still in the intensive
care unit [ICU]: MV[]; and discharged alive from the ICU or dead) subsequently divided according to the presence or absence of ventilator-
associated lower respiratory tract infection (VA-LRTI) in the patient (LRTI [þ] or LRTI[], respectively). Note the slightly higher mortality for
patients having ARDS without (green) or with (red) previous VA-LRTI. There was a smaller proportion of patients discharged after VA-LRTI in
the ARDS subgroup (cyan bars).
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Patients with ARDS were more frequently admitted due to
medical reasons, had higher Sequential Organ Failure Assess-
ment score, more comorbid conditions (chronic obstructive
pulmonary disease, diabetes, alcoholism, and hematological
cancer), and had a higher ICU mortality. The occurrence of
microbiologically confirmed VAT and VAP was not different
between patients with and without ARDS. A comparison
between patients with and without ARDS is shown in Supple-
mental Table 1. Patients with ARDS who died in the ICU were
older, had higher illness severity, and more frequently had
cancer (Table 1). Although ICU mortality was higher for
patients having ARDS with VAT or VAP (VAT 22 [40.7%]
of 54 and VAP 26 [46.4%] of 56; Figure 2), this did not reach
statistical significance (P ¼.261). The results were unchanged
if VAT/VAP was grouped in VA-LRTI (mortality 48 [43.6%]
of 110 vs 148 [35.7%] 414 in patients having ARDS without
VA-LRTI; P ¼.158).
Results for multivariate logistic regression for ICU mortal-
ity are shown in Table 2. Neither VA-LRTI nor VAT or VAP
individually was associated with worse outcome in both mod-
els. Bootstrap errors were small (Table 2). This means that if
data were hypothetically replicated 105 times, the results for the
logistic regression would vary little between all possible data
combinations. This suggests that the model is probably robust
and was probably not overfitted.
In the whole TAVeM study, the attributable mortality of
ARDS was 4.5% (95% confidence interval [CI]: 1.9%-7.2%)
while attributable mortality for VA-LRTI was 3.2% (95% CI:
0.2%-6%). In the subgroup of patients without ARDS, attribu-
table mortality for VA-LRTI was 7.4% (95% CI: 3.4%-11.4%);
while in the subgroup of patients with ARDS, no attributable
mortality for VA-LRTI was found (16.6%; 95% CI:44% to
10.9%). When only VAP was considered, its attributable mor-
tality slightly increased in patients without ARDS (8.5%; 95%
CI: 5.5%-11.6%) but remained nonsignificant in patients with
ARDS.
The results of the sequential importance of variables in ran-
dom forest models are shown in Figure 3. Simplified Acute
Physiology Score 2 was the most important variable, followed
by Barthel index and presence of VA-LRTI. In the whole pop-
ulation and in the non-ARDS subgroup, the relative importance
of SAPS 2 decreased over time, while the importance of
Barthel index and occurrence of VA-LRTI increased. In the
ARDS population, however, relative importance fluctuated
over time, with no suggestion of increase in the importance
of VA-LRTI for the model over time. The relative Gini
decrease over time for VA-LRTI remained below 10% during
most of the time.
Although both ICU LOS and duration of MV were higher in
patients with LRTI (Supplemental Figures 1 and 2), there
was no significant association between both outcomes and
VA-LRTI in competing risk analysis in patients with ARDS
(hazard ratio [HR]: 0.82; 95% CI: 0.53-1.27, P ¼ .38 and HR:
0.87, 95% CI: 0.58-1.30, P ¼ .87 and P ¼.50).
Discussion
Ventilator-associated lower respiratory tract infection has been
a matter of debate, especially regarding its attributable mortal-
ity in specific clinical scenarios. This analysis of a large pop-
ulation that comprised almost 3000 patients from 114 ICUs in
8 countries found that the occurrence of VA-LRTI in patients
with ARDS had no major impact in ICU mortality nor was it
associated with increase in ICU LOS or duration of MV.
Although the relative importance of VA-LRTI in a predictive
model for mortality increased over time in patients without
ARDS, it remained small (with a trend of decrease in impor-
tance) in patients with ARDS. This resulted in a global attri-
butable mortality of VA-LRTI close to 3% but in a neglectable
attributable mortality in the ARDS subgroup.
The most important finding in our analysis is the lack of
association between VAP and mortality in patients with ARDS.
This is something that needs to be analyzed cautiously because
the most important risk factor for monitoring response to ther-
apy in patients with VAP might be the improvement of oxyge-
nation with either P/F ratio alone or in combination with other
clinical parameters of the Clinical Pulmonary Infection
Table 1. Comparison Between Survivor and Nonsurvivor Patients
With ARDS.
Characteristics Survivors Death P
Number of patients 328 196
Age, mean (SD) 60.3 (16.5) 64.2 (5.4) .07
Male gender, n (%) 192 (58.5) 118 (60.2) .77
Admission type, n (%) .77
Medical 256 (78.0) 148 (75.5)
Surgical 54 (16.5) 37 (18.9)
Trauma 18 (5.5) 11 (5.6)
SAPS 2, mean (SD) 48.2 (18.7) 55.9 (18.6) <.001
Barthel, mean (SD) 85.4 (28.3) 81.3 (29.4) .11
SOFA, mean (SD) 8.4 (3.9) 9.6 (4.0) .001
COPD, n (%) 45 (13.7) 26 (13.3) .99
Chronic renal failure, n (%) 40 (12.2) 33 (16.8) .18
Diabetes, n (%) 69 (21.0) 53 (27.0) .14
Alcoholism, n (%) 28 (8.5) 19 (9.7) .77
Nonmetastatic cancer, n (%) 28 (8.5) 29 (14.8) .04
Metastatic cancer, n (%) 5 (1.5) 10 (5.1) .03
Hematologic cancer, n (%) 12 (3.7) 24 (12.2) <.001
AIDS, n (%) 2 (0.6) 5 (2.6) .14
Worsening X-ray, n (%) 42 (12.8) 33 (16.8) .25
Worsening gas exchange,
n (%)
48 (14.6) 42 (21.4) .06
Time to infection,
median (IQR)
7.0 (4.0-11.0) 8.0 (5.0-12.2) .12
VA-LRTI, % .26
None 266 (81.1) 148 (75.5)
VAT 32 (9.8) 22 (11.2)
VAP 30 (9.1) 26 (13.3)
Abbreviations: AIDS, acquired immunodeficiency syndrome; ARDS, acute
respiratory distress syndrome; COPD, chronic obstructive pulmonary disease;
IQR, interquartile range; SAPS 2, Simplified Acute Physiology Score 2; SD,
standard deviation; SOFA, Sequential Organ Failure Assessment; VA-LRTI,
ventilator-associated lower respiratory tract infections; VAP, ventilator-
associated pneumonia; VAT, ventilator-associated tracheobronchitis.
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Score.16 Therefore, suspicion for VA-LRTI could be triggered
by a worse clinical scenario with persistently impaired, slowly
resolving, or worsening oxygenation in patients with ARDS,
which could lead to microbiological testing only in the setting
of a worsening clinical scenario. Since our study was not
designed to quantify the oxygenation impairment in the
selected sample, we could not evaluate course in oxygenation
improvement, which would be necessary to better understand
our results. It should also be taken into account the inherent
difficulties in diagnosing VA-LRTI in ARDS since these
patients have bilateral radiographic infiltrates and present with
worsening of oxygenation. In this context, diagnosis without
microbiological confirmation may be unreliable. Ventilator-
associated tracheobronchitis diagnosis may be even more cum-
bersome since VAT can only be assumed in the context of
absence of new or progressive radiographic changes and
demands tracheal aspirates for microbiologically confirma-
tion.17 Either way, our results suggest that when VA-LRTI is
suspected in patients with ARDS, the presence of positive cul-
tures obtained from the respiratory tract coupled with clinical
picture of respiratory infection is not associated with worse
ICU mortality, regardless of radiographic findings (which may
be subjective and discriminate between VAT and VAP).
One other important aspect is the trend in the variable
importance over time for illness severity (SAPS 2), a proxy
of baseline performance (Barthel index), and the occurrence
of VA-LRTI. In patients without ARDS, the relative impor-
tance of a global illness severity marker as a mortality predictor
decreased as early as after the first day of ICU admission, while
Barthel index and occurrence of VA-LRTI increased their rela-
tive importance up to day 14. This finding is in accordance with
other reports that suggested that baseline health status and
comorbidities may become the major determinants of outcome
early in the course of critical illness.14 In contrast, in patients
with ARDS, the relative contribution of the 3 aforementioned
variables was relatively constant; if any, there was a trend in the
reduction of the already questionable importance of VA-LRTI
during time. This may suggest that for the most severe critically
ill patients, the baseline illness severity at admission is the
major contributor to short-term outcome.
In one of the first multicenter studies of VA-LRTI in ARDS,
Markowicz et al found results that are similar to ours.7 Micro-
biologically confirmed VAP occurred in 36.5% of the 134
patients with ARDS and was not associated with higher ICU
Figure 2. Intensive care unit (ICU) mortality stratified according to (A) the presence or absence of ventilator-associated lower respiratory tract
infection (VA-LRTI) or (B) occurrence of ventilator-associated tracheobronchitis (VAT), ventilator-associated pneumonia (VAP), or no-LRTI.
Table 2. Logistic Regression Results for ICU Mortality.
Variable OR CI P Bootstrap SE Bootstap CI
VA-LRTI model
SAPS 2 1.02 1.01-1.03 <.001 0.005 1.01-1.03
Barthel index 0.99 0.98-1.00 .06 0.003 0.98-1.00
Worsening gas
exchange
1.46 0.82-2.60 .19 0.306 0.79-2.65
VA-LRTI 1.07 0.62-1.83 .80 0.280 0.61-1.85
VAT/VAP model
SAPS 2 1.02 1.01-1.03 <.001 0.005 1.01-1.03
Barthel index 0.99 0.98-1.00 .06 0.003 0.98-1.00
Worsening gas
exchange
1.36 0.74-2.50 .31 0.325 0.71-2.56
VAT 0.94 0.49-1.77 .87 0.338 0.48-1.83
VAP 1.30 0.61-2.74 .49 0.399 0.59-2.84
Abbreviations: CI, confidence interval; ICU, intensive care unit; OR, odds ratio;
SAPS 2, Simplified Acute Physiology Score 2; SE, standard error; VA-LRTI,
ventilator-associated lower respiratory tract infections; VAP, ventilator-
associated pneumonia; VAT, ventilator-associated tracheobronchitis.
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mortality, although length of MV was longer when VAP
occurred. In our analysis, when appropriate competing risks
were applied, no effect of VA-LRTI on duration of MV or ICU
LOS could be found. Several other small single-center studies
assessed the impact of VAP in patients with ARDS, with varied
results. More recently, Forel et al obtained similar results in
patients ventilated according to a lung protective strategy.8
Using data from the PROSEVA study, Ayzac et al found that
when VAP was treated as a time-dependent variable, it was
associated with higher mortality in patients with ARDS.4 Our
data exceed previous reports by considering both VAT and
VAP in this population and by evaluating variable importance
over time. Taken together, our findings suggest that in the
population of severely ill patients with ARDS, microbiologi-
cally confirmed VA-LRTI may be more a marker than a reason
for higher mortality.
Our analysis has several limitations. First, our sample size is
reasonably small, which may have limited the number of con-
founders to be accounted for in regression models. The wide
CIs highlight that our data are compatible with either an
increase or decrease in mortality associated with VA-LRTI.
We only had a very short-term end point (ICU mortality)
available, which therefore hinders us from assessing whether
VA-LRTI could contribute to mortality after ICU discharge. As
we did not record specific interventions and process of care
measures, we could not correct for many factors known to be
associated with ARDS mortality such as inappropriate ventila-
tory settings, information on lung mechanics, and use of other
treatments such as neuromuscular blockade. This may in part
explain why we could not find specific variables associated
with mortality in patients having ARDS with VA-LRTI.
Second, the attributable mortality of ARDS was low in our
population, which may be related to the overall low ARDS
mortality in TAVeM population (37.4%); nevertheless, this
value is close to some recent reports18 and may be related to
the fact that even patients with mild ARDS were included in the
analysis. No data on ARDS severity other than global severity
of illness markers (including P/F ratio) were consistently
available; therefore, we cannot determine whether these find-
ings may be limited to patients with severe ARDS. We have
also not assessed the impact of multiple events (ie, several
episodes of VA-LRTI) on outcome. Finally, we only included
microbiologically confirmed VA-LRTI; since the sensibility
of respiratory track samples is not perfect, some patients with
VA-LRTI may not have been included.
Conclusion
Occurrence of VA-LRTI in patients with ARDS may not be
associated with ICU mortality nor ICU LOS or duration of MV.
Figure 3. Relative variable importance for sequential random forest models performed from inclusion in the study and up to 14 days; panels (B)
and (C) present the results for the non-acute respiratory distress syndrome (non-ARDS) and ARDS subgroups. Patients included in each model
included those still alive in the intensive care unit (ICU) until the model reference day and which did not have ventilator-associated lower
respiratory tract infection (VA-LRTI) until that moment. The relative importance was calculated as the mean Gini decrease for each variable
divided over the total sum of Gini values for the model. Notice how the relative importance of Simplified Acute Physiology Score 2 (SAPS 2)
decreased in patients without ARDS while the importance of Barthel index and VA-LRTI increased. For patients with ARDS, no clear trend was
seen, with a questionable decrease in the importance of VA-LRTI over time.
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